Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 2 ( February, 2021 ) > List of Articles


Presepsin: A Promising Biomarker for Sepsis

Citation Information : Presepsin: A Promising Biomarker for Sepsis. Indian J Crit Care Med 2021; 25 (2):117-118.

DOI: 10.5005/jp-journals-10071-23741

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2021; The Author(s).


Sepsis is the most common cause of mortality in non-cardiac ICUs. The quest for early diagnosis and treatment has led to the discovery of many biomarkers. In this issue, Abdelshafey et al. have evaluated presepsin, a novel biomarker for early detection of sepsis. Presepsin is formed by cleavage of N-terminal of soluble CD14 (sCD14) which is a member of the Toll-like receptors (TLRs). Studies have found a higher level of presepsin in septic patients and values above 946 ng/L correlated well with gram-negative bacterial sepsis.

  1. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet 2018;392(10141):75–87. DOI: 10.1016/S0140-6736(18)30696-2.
  2. Scheer CS, Fuchs C, Gründling M, Vollmer M, Bast J, Bohnert JA, et al. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect 2019;25(3):326–331. DOI: 10.1016/j.cmi.2018.05.016.
  3. Abdelshafey EE, Nasa P, Elgohary AE, et al. Role of presepsin for diagnosis of sepsis and ICU mortality. A prospective controlled study. Indian J Crit Care Med 2021;25(2):153–157.
  4. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care 2020;24(1):287. DOI: 10.1186/s13054-020-02993-5.
  5. Ryoo SM, Han KS, Ahn S, Shin TG, Hwang SY, Chung SP, et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: a multicenter prospective registry-based observational study. Sci Rep 2019;9(1):6579. DOI: 10.1038/s41598-019-42972-7
  6. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med 2014;5(1):16–19. DOI: 10.5847/wjem.j.issn.1920-8642.2014.061.002.
  7. Memar MY, Baghi HB. Presepsin: a promising biomarker for the detection of bacterial infections. Biomed Pharmacother 2019;111:649–656. DOI: 10.1016/j.biopha.2018.12.124.
  8. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11(5):234–238. DOI: 10.1007/s10156-005-0400-4.
  9. Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care 2015;19(1):323. DOI: 10.1186/s13054-015-1032-4.
  10. Yoon SH, Kim EH, Kim HY, Ahn JG. Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis. BMC Infect Dis 2019;19(1):760. DOI: 10.1186/s12879-019-4397-1.
  11. Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial [Published correction appears in Intensive Care Med 2015;41(9):1736]. Intensive Care Med 2015;41(1):12–20. DOI: 10.1007/s00134-014-3514-2.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.